03:21 , Aug 10, 2019 |  BioCentury  |  Regulation

Timeline of a debacle: Novartis missteps hold lessons for diligence, new modalities

Aside from all the questions about who knew what when, and how they should have acted, the Zolgensma data fiasco reveals that Novartis’ due diligence team missed some warning signs. The case has the hallmarks...
19:30 , Aug 7, 2019 |  BC Extra  |  Financial News

VCs recapitalize Cleave around next-gen molecule

Seven of the 10 investors in Cleave Therapeutics' existing syndicate have agreed to recapitalize the company with a new $12 million round, with which Cleave will test a second-generation cancer compound following a toxicity snag...
02:03 , Jun 15, 2019 |  BioCentury  |  Politics, Policy & Law

Signs of hope on patent eligibility reform as Congress weighs arguments

The wait is still far from over for fixing the rules on what can be patented -- a move that could give diagnostics a fighting chance of becoming commercially viable. That said, a three-day Congressional...
23:49 , Jun 7, 2019 |  BioCentury  |  Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try...
00:37 , May 10, 2019 |  BC Innovations  |  Product Development

Congress pushes to reform patent eligibility, biotechs say not enough

Congress has taken the first step towards fixing a key problem with patent policy that has crippled the diagnostics industry and disrupted development of other life science inventions, but its proposed solution falls short for...
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
02:16 , Apr 5, 2019 |  BC Innovations  |  Targets & Mechanisms

Breaking up Hippo to tame proliferation

Drug developers are creating a new class of compounds that disrupt a protein-protein interaction in the Hippo pathway that goes awry in cancers and fibrotic diseases. At least two programs are poised to enter the...
22:37 , Apr 3, 2019 |  BC Extra  |  Politics & Policy

Express Scripts offers option to cap insulin costs

As congressional pressure mounts on drug companies and PBMs over rising insulin costs, Express Scripts presented clients with a new option Wednesday that could lessen the burden on patients in the near term. Express Scripts...
23:07 , Mar 25, 2019 |  BC Extra  |  Financial News

Biogen announces $5B stock buyback on heels of Alzheimer’s hit

For the second time in a year, Biogen has announced a share repurchase program on the heels of bad news from an Alzheimer's candidate. This time, the big biotech has authorized the repurchase of $5...